Challenges in translational research: MDMA in the laboratory versus therapeutic settings.
Harriet de Wit, Anya K Bershad, Charles Grob
Journal of psychopharmacology (Oxford, England) March 1, 2022 Peer reviewed DOI: 10.1177/02698811211015221 via PubMed
Summary
Despite MDMA's promise for mental disorders, understanding its precise therapeutic mechanisms remains a challenge. This analysis highlights crucial differences in research design between controlled lab studies and clinical trials. Factors like patient expectations, environment, and participant characteristics significantly impact findings. Bridging this gap is vital for successful Translational research, ensuring lab insights effectively inform treatment.
Abstract
Despite substantial progress in the use of mind-altering drugs to treat psychiatric disorders, the psychological processes through which these drugs change mood or behavior are poorly understood. Controlled laboratory studies with well-defined psychological constructs are valuable to understand how these drugs manifest their therapeutic benefit. However, there are substantial methodological differences between clinical studies investigating therapeutic outcome and laboratory studies investigating the processes that might underlie the therapeutic effects. Here, we examine some of these differences using the example of 3,4-methylenedioxymethamphetamine (MDMA). We review differences in expectancies, social and physical context, participant characteristics, pharmacological factors, and outcome measures in studies with participants who do or do not have psychiatric diagnoses. We describe the challenges and opportunities in translating findings from laboratory studies to the clinic and identify ways to bridge the gap between these approaches.